Tizanidine
Product Images NDC 67296-1417

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 67296-1417). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Epm 15 Ct (67296 1417 7)

Epm 15 Ct (67296 1417 7)
The text is a pharmaceutical label for Tizanidine tablets manufactured by Dr. Reddy's Laboratories Limited. The tablets come in a package of 15 and are only available with a prescription. The lot number is 000939X1 and the expiration date is 04/23. The package insert contains dosage information for adults. The tablets should be stored at a controlled room temperature between 20-25 C (68-77 F). The NDC code for the product is 67296-1417-7, and it is distributed by Redpharm Drug in Eden Prairie, MN 55344.*
FDA Label Image

Container1 (Container1)

FDA Label Image

Container2 (Container2)

FDA Label Image

Container3 (Container3)

FDA Label Image

Container4 (Container4)

FDA Label Image

Fig1 (Fig1)

Fig1 (Fig1)
This text provides a table showing the plasma Tzanidine concentration (in ng/mL) at different times after taking different doses of Tzanidine tablets and capsules with or without food. The table lists four scenarios: taking 2x 4mg Tzanidine tablets with food, taking 2x 4mg Tzanidine tablets without food, taking 2x 4mg Tzanidine capsules with food and taking 2x 4mg Tzanidine capsules without food. The table also includes a note about the time elapsed from dosing.*
FDA Label Image

Fig2 (Fig2)

FDA Label Image

Fig3 (Fig3)

Fig3 (Fig3)
The text describes the improvement in Ashworth Score by using Zanidine at a mean dose of 28.6 mg, observed at week 3 and the end of maintenance endpoint, which is the study week 7, using the last observation carried forward.*
FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.